# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K072732   
B. Purpose for Submission: To obtain device clearance   
C. Measurand: Trypanosoma cruzi (T. cruzi)   
D. Type of Test: ELISA   
E. Applicant: Ortho Clinical Diagnostics   
F. Proprietary and Established Names: ORTHO® T. Cruzi ELISA Test System

# G. Regulatory Information:

1. Regulation section: 866.3870

2. Classification: 1

3. Product code: MIU

4. Panel: Microbiology

# H. Intended Use:

1. Intended use(s):

ORTHO T. cruzi ELISA Test System is an enzyme-linked immunosorbent assay for the in vitro qualitative detection of antibodies (Immunoglobulin G) to Trypanosoma cruzi (T. cruzi) in human adult serum (glass, plastic, or serum separator tubes) and plasma (EDTA, lithium heparin or citrate) using whole-cell lysate antigens. Reactive assay results are presumptive evidence of past infection, and in conjunction with other serological and clinical information, may be used for the laboratory diagnosis of individuals with Chagas’ disease.

Definitive diagnosis of an acute phase of infection (including acute congenital infection) must be made by alternate methods, e.g., hemoculture, blood smear.

This test is not intended for use on samples of cord blood or screening blood or plasma donors.

2. Indication(s) for use:

ORTHO T. cruzi ELISA Test System is an enzyme-linked immunosorbent assay for the in vitro qualitative detection of antibodies (Immunoglobulin G) to Trypanosoma cruzi (T. cruzi) in human adult serum (glass, plastic, or serum separator tubes) and plasma (EDTA, lithium heparin or citrate) using whole-cell lysate antigens. Reactive assay results are presumptive evidence of past infection, and in conjunction with other serological and clinical information, may be used for the laboratory diagnosis of individuals with Chagas’ disease.

Definitive diagnosis of an acute phase of infection (including acute congenital infection) must be made by alternate methods, e.g., hemoculture, blood smear.

This test is not intended for use on samples of cord blood or screening blood or plasma donors.

3. Special conditions for use statement(s):

NA

4. Special instrument requirements: NA

# I. Device Description:

The assay procedure is a three-stage test carried out in a microwell coated with lysate (antigens) prepared from T. cruzi. In the first stage, test specimen, Negative Control, and Positive Calibrator are diluted directly in the test well containing Specimen Diluent, and incubated for a specified length of time. If antibodies to $T .$ . cruzi are present, antigenantibody complexes will form on the microwell surface. If antibodies to $T .$ . cruzi are absent, complexes will not form. Unbound antibodies in the sample will be removed during the subsequent wash step.

In the second stage, murine monoclonal antibody conjugated with Horseradish Peroxidase (Conjugate) is added to the test well. The Conjugate binds specifically to the antibody portion of the antigen-antibody complex. If complexes are not present, the unbound Conjugate is removed by the subsequent wash step.

In the third stage, an enzyme detection system composed of $o$ -phenylenediamine (OPD) and hydrogen peroxide is added to the test well. If bound Conjugate is present, the OPD will be oxidized, resulting in a colored end product. Sulfuric acid is then added to stop the reaction. The color intensity depends on the amount of bound Conjugate and, therefore, is a function of the concentration of antibodies to $T .$ cruzi present in the specimen. The intensity of color in the substrate solution is then determined with a microwell reader (spectrophotometer) designed to measure light absorbance in a microwell.

# J. Substantial Equivalence Information:

1. Predicate device names: Hemagen Chagas Kit (EIA Method) Wiener Laboratories T. cruzi – Enzyme Linked Immunosorbent Assay,

2. Predicate 510(k) numbers:

K930272   
K023889

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>DeviceCharacteristic</td><td rowspan=1 colspan=1>ORTHO T. cruzi ELISA TestSystem</td><td rowspan=1 colspan=1>K930272Hemagen Chagas&#x27; Kit(EIA Method) −Hemagen Diagnostics, Inc.</td><td rowspan=1 colspan=1>K023889Enzyme LinkedImmunosorbent Assay,T. cruzi -Wiener Laboratories</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>.. for the in vitro qualitativedetection of antibodies toTrypanosoma cruzi (T. cruzi)</td><td rowspan=1 colspan=1>for the detection of circulatingantibodies to Trypanosoma cruzi,the causative agent of Chagas&#x27;disease</td><td rowspan=1 colspan=1>Qualitative detection ofantibody to Trypanosoma cruzi,the causative agent for Chagas&#x27;disease in human serum orplasma.</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>Assay results, in conjunction withother serological and clinicalinformation, may be used for thelaboratory diagnosis ofindividuals with Chagas&#x27; disease.</td><td rowspan=1 colspan=1>When used according toinstructions, the kit is useful inexhibiting prior exposure to T.cruzi and as an aid in thediagnosis of Chagas&#x27; disease.</td><td rowspan=1 colspan=1>When using according toinstructions, the kit is useful inestablishing prior exposure toT. cruzi and as an aid in thediagnosis of Chagas&#x27; disease.</td></tr><tr><td rowspan=1 colspan=1>Basic Principle</td><td rowspan=1 colspan=1>Enzyme-linked immunosorbentassay, ELISA</td><td rowspan=1 colspan=1>Enzyme-linked immunosorbentassay, ELISA</td><td rowspan=1 colspan=1>Enzyme-linked immunosorbentassay, ELISA</td></tr><tr><td rowspan=1 colspan=1>Where used</td><td rowspan=1 colspan=1>CLIA Certified ClinicalLaboratory</td><td rowspan=1 colspan=1>CLIA Certified ClinicalLaboratory</td><td rowspan=1 colspan=1>CLIA Certified ClinicalLaboratory</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum or Plasma(EDTA, lithium heparin orcitrate</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum or Plasma(heparin, EDTA, and citratebased anticoagulants)</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Trypanosoma spp.(T. cruzi Tulahuen)</td><td rowspan=1 colspan=1>Trypanosoma spp.</td><td rowspan=1 colspan=1>Recombinant T. cruzi antigensfrom the trypomastigoteparasite stage: #1, #2, #13,#30, and #36)</td></tr><tr><td rowspan=1 colspan=1>Antigen Prep</td><td rowspan=1 colspan=1>Whole cell lysate coated ontoplastic microwells</td><td rowspan=1 colspan=1>Purified antigens from cultured T.cruzi organisms</td><td rowspan=1 colspan=1>Recombinant technology</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>20 μL</td><td rowspan=1 colspan=1>10 μL</td><td rowspan=1 colspan=1>10 μL</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Diluted sample is incubated withthe antigen prep. After anappropriate time the serumdilution in removed, and theantigen prep is washed. Theantigen prep is overlaid withantibody labeled with anchromogenic substrate</td><td rowspan=1 colspan=1>Diluted sample is incubated withthe antigen prep. After anappropriate time the serumdilution in removed, and theantigen prep is washed. Theantigen prep is overlaid withantibody labeled with anchromogenic substrate</td><td rowspan=1 colspan=1>Diluted sample is incubatedwith the antigen prep. After anappropriate time the serumdilution in removed, and theantigen prep is washed. Theantigen prep is overlaid withantibody labeled with anchromogenic substrate</td></tr><tr><td rowspan=1 colspan=1>ConjugateAntibody</td><td rowspan=1 colspan=1>Anti-human IgG</td><td rowspan=1 colspan=1>Anti-human IgG</td><td rowspan=1 colspan=1>Anti-human IgG</td></tr><tr><td rowspan=1 colspan=1>Tracer</td><td rowspan=1 colspan=1>Horseradish peroxidase with aSubstrate Solution made fromSubstrate Buffer and OPD Tablets</td><td rowspan=1 colspan=1>Horseradish peroxidase withsubstrate 3, 3&#x27;, 5, 5&#x27;tetramethylbenzidine (TMB)</td><td rowspan=1 colspan=1>Horseradish peroxidase withsubstrate 3, 3&#x27;, 5, 5&#x27;tetramethylbenzidine (TMB)</td></tr><tr><td rowspan=2 colspan=1>AntibodiesDetection</td><td rowspan=2 colspan=1>The antibody-HRP bound to thewhole cell lysate-antibodycomplex reacts with the OPDproducing a colored end product.The OD is readspectrophotometrically</td><td rowspan=1 colspan=1>The antibody-HRP bound to thewhole cell lysate-antibodycomplex reacts with the TMBproducing a colored end product.</td><td rowspan=1 colspan=1>The antibody-HRP bound tothe recombinant antigens-antibody complex reacts withthe TMB producing a colored</td></tr><tr><td rowspan=1 colspan=1>The OD is readspectrophotometrically</td><td rowspan=1 colspan=1>end product. The OD is readspectrophotometrically</td></tr></table>

N.B.: Shaded areas show differences between the device and the predicates

K. Standard/Guidance Document Referenced (if applicable): NA

L. Test Principle: See device description

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: NA a. Precision/Reproducibility:

The intra-assay (within plate) and inter-assay (between plates) precision of the ORTHO T. cruzi ELISA Test System was evaluated using an eight-member precision panel. The precision panel consisted of three moderate to strongly reactive samples, three reactive samples near the assay cutoff (approximately $1 . 5 - 2 . 0 \mathrm { S } / \mathrm { C } )$ , and two nonreactive samples. The panel was tested at three external sites using three different kit lots by the semi-automated processing method. Ten replicates each of the eightmember panel were assayed on a single occasion per day on nine different days by two technologists for a total of 4319 observations (one observation for R7 was a statistical outlier). Mean signal to cutoff $\mathrm { ( S / C ) }$ , standard deviation (SD), and coefficient of variation $( \mathrm { C V } \% )$ ) results are presented in the table below.

<table><tr><td rowspan=2 colspan=1>PanelMember</td><td rowspan=2 colspan=1>NumberTested</td><td rowspan=2 colspan=1>Mean ORTHOT. cruzi ELISAS/C</td><td rowspan=1 colspan=2>Inter-assay1</td><td rowspan=1 colspan=2>Intra-assay^2</td><td rowspan=1 colspan=2>Total3</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>R1</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>5.954</td><td rowspan=1 colspan=1>0.258</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.324</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.492</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>6.424</td><td rowspan=1 colspan=1>0.306</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.324</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.501</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>R3</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>6.647</td><td rowspan=1 colspan=1>0.338</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.345</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.554</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>R4</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>1.946</td><td rowspan=1 colspan=1>0.089</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.143</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.189</td><td rowspan=1 colspan=1>9.7</td></tr><tr><td rowspan=1 colspan=1>R5</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>1.909</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.128</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>0.180</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>R6</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>2.173</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.134</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>0.207</td><td rowspan=1 colspan=1>9.5</td></tr><tr><td rowspan=1 colspan=1>R7</td><td rowspan=1 colspan=1>539</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>N/A4</td><td rowspan=1 colspan=1>0.025</td><td rowspan=1 colspan=1>N/A4</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>N/A4</td></tr><tr><td rowspan=1 colspan=1>R8</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>0.101</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>N/A4</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>N/A4</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>N/A4</td></tr><tr><td rowspan=1 colspan=9>  e         pa  2 Within Plate (Between Replicate): Variability of the assay performance from replicate to replicate3Total: Inter-assay and Intra-assay variability4 % CVs are not meaningful when S/C approaches zero</td></tr></table>

b. Linearity/assay reportable range: NA   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): NA

d. Detection limit:

NA

# e. Analytical specificity:

The specificity of the ORTHO T. cruzi ELISA Test System was evaluated using 616 samples from individuals with infections or clinical conditions that might potentially exhibit cross reactivity when tested with the assay. The table below shows the numbers and types of samples tested.

<table><tr><td rowspan=1 colspan=1>Potentially Cross Reacting Condition or DiseaseState</td><td rowspan=1 colspan=1>Number ofSpecimens</td><td rowspan=1 colspan=1>Nonreactive(%)</td><td rowspan=1 colspan=1>RepeatedlyReactive (%)</td></tr><tr><td rowspan=1 colspan=1>Leishmanial</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>21 (21.0)</td><td rowspan=1 colspan=1>79 (79.0)</td></tr><tr><td rowspan=1 colspan=1>Malaria</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>94 (97.9)</td><td rowspan=1 colspan=1>2 (2.1)</td></tr><tr><td rowspan=1 colspan=1>Schistosomiasis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>29 (96.7)</td><td rowspan=1 colspan=1>1 (3.3)</td></tr><tr><td rowspan=1 colspan=1>Pre-Vaccination with Influenza Vaccine</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>35 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Post-Vaccination with Influenza Vaccine</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>35 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Lupus Erythematosus (ANA titer &gt; 1:640)</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Arthritis (RF &gt; 30 IU or titer &gt; 1:320)</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Polyclonal Gammopathies</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Monoclonal Gammopathies</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Multiple Leukocyte Alloantibodies</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Multiple Red Cell Alloantibodies</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Epstein-Barr Virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Herpes Simplex Virus Type 1</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Hepatitis B</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Hepatitis C</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Human Immunodeficiency Virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Human T-Cell Lymphotropic Virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis gondii</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5 (100.0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Paracoccidioides brasiliensis</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3 (60.0)</td><td rowspan=1 colspan=1>2 (40.0){2</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>616</td><td rowspan=1 colspan=1>532 (86.4)</td><td rowspan=1 colspan=1>84 (13.6)</td></tr><tr><td rowspan=1 colspan=4>Leismania specimens were collected in India where T. cruz is not endemic and these specimens are presumedto be T. cruzi antibody negativeThee to speciens were obtained fom Argentina, where . cruzi inection is ndemic. Boh speciens wereRIPA positive.</td></tr></table>

Among the 100 subjects with Leishmania infection, 21 $( 2 1 . 0 \% )$ were nonreactive and 79 $( 7 9 . 0 \% )$ were repeatedly reactive. The specimens were obtained in India where $T .$ cruzi is not endemic and, therefore, the most probable $T .$ cruzi antibody status of the 100 Leishmania specimens is negative. The ORTHO T. cruzi ELISA Test System may yield falsely reactive results among test subjects with no Leishmania infection.

Of the 516 non-Leishmania specimens, 511 $( 9 9 . 0 \% )$ were nonreactive and five $( 1 . 0 \% )$ were repeatedly reactive. Three of the five repeatedly reactive specimens (1 syphilis, and 2 malaria, $P$ . falciparum) were RIPA negative. Two of the five repeatedly reactive specimens were obtained from among the five test subjects with Paracoccidioides brasiliensis infection. These two specimens were RIPA positive and were obtained from a T. cruzi endemic area. Whether these represent false positive for $T .$ . cruzi infection due to cross reactivity in both ELISA and RIPA or co-infection with $P$ . brasiliensis and T. cruzi is not known.

$f .$ Assay cut-off: NA

2. Comparison studies: a. Method comparison with predicate device: See 3c. b. Matrix comparison: NA

3. Clinical studies:

a. Clinical Sensitivity: See 3. c.   
$b$ . Clinical specificity: See 3. c.   
c. Other clinical supportive data (when a. and b. are not applicable):

# Clinical Performance

A multi-center study was conducted to establish the clinical performance of the ORTHO T. cruzi ELISA Test System among individuals at high or low risk for T. cruzi infection selected under well-defined inclusion and exclusion criteria but without regard to a known or previously determined T. cruzi antibody assay result. Statistical testing was performed to ensure that the distribution of ORTHO T. cruzi ELISA $\mathrm { S / C }$ values was homogeneous across the two testing sites participating in the study (Camp Hill, PA and Newark, NJ), and that the test results could be combined for analysis. Individuals presumed to be $T .$ cruzi antibody positive by parasite detection methods or by serological methods were evaluated separately.

Specimens from subjects at high risk for T. cruzi infection $\scriptstyle ( \mathrm { N } = 5 7 4$ ) were collected in Bolivia $( 2 8 . 9 \% )$ , Colombia $( 1 3 . 1 \% )$ , Guatemala $( 2 3 . 3 \% )$ , Mexico $( 8 . 7 \% )$ and Nicaragua $( 2 6 . 0 \% )$ . The population was $4 4 . 9 \%$ female and $5 5 . 1 \%$ male, and ranged in age from 18 to 88 years.

Specimens from subjects at low risk for $T .$ cruzi infection but with signs or symptoms similar to Chagas’ disease $\scriptstyle ( \mathrm { N } = 3 0 0 )$ ) were collected in the U.S. from Black $( 7 . 7 \% )$ and Caucasian $( 9 2 . 3 \% )$ subjects. The population was $4 3 . 0 \%$ female and $5 7 . 0 \%$ male, and ranged in age from 21 to 93 years. Specimens from low risk pregnant women $( \mathrm { N } { = } 2 0 0 )$ ) were obtained in the U.S. from subjects in their first $( 2 1 . 5 \% )$ , second $( 3 8 . 5 \% )$ or third $( 4 0 . 0 \% )$ trimester.

Comparator testing was performed with a validated T. cruzi IFA. Additional, more specific supplemental testing was performed with a validated T. cruzi radioimmunoprecipitation assay (RIPA).

# ORTHO T. cruzi ELISA and T. cruzi IFA Results among High Risk and Low Risk Subjects

Specimens from 1074 subjects at high or low risk for T. cruzi infection were tested with a comparator T. cruzi IFA and with the ORTHO T. cruzi ELISA Test System. The results are presented in the following table.

<table><tr><td rowspan=1 colspan=4>ORTHO T. cruzi ELISA vs. T. cruzi IFA Results (N=1074)</td></tr><tr><td rowspan=2 colspan=1>ORTHO T. cruzi ELISAResult</td><td rowspan=1 colspan=2>T. cruzi IFA Result</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Repeatedly Reactive</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>973</td><td rowspan=1 colspan=1>976</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>989</td><td rowspan=1 colspan=1>1074</td></tr><tr><td rowspan=1 colspan=4>1 These three specimens were also negative with the T. cruzi RIPA.2 Ten of these 16 specimens were also positive with the T. cruzi RIPA.</td></tr></table>

# Percent Agreement

The table below summarizes the percent agreement between the ORTHO T. cruzi ELISA and the T. cruzi IFA. Data are listed by population and overall, with positive and negative percent agreement and $9 5 \%$ exact confidence intervals (CI).

<table><tr><td rowspan=1 colspan=5>Positive and Negative Percent Agreement of the ORTHO T. cruzi ELISA with the T. cruzi IFA by StudyPopulation (N=1074)</td></tr><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>Positive PercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidence Interval</td><td rowspan=1 colspan=1>Negative PercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidence Interval</td></tr><tr><td rowspan=1 colspan=1>High Risk</td><td rowspan=1 colspan=1>96.47%(82/85)</td><td rowspan=1 colspan=1>90.03% - 99.27%</td><td rowspan=1 colspan=1>96.93%(474/489)</td><td rowspan=1 colspan=1>94.99% - 98.27%</td></tr><tr><td rowspan=1 colspan=1>Low Risk</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100%(300/300)</td><td rowspan=1 colspan=1>98.78% - 100%</td></tr><tr><td rowspan=1 colspan=1>PregnancyLow Risk</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>99.50%(199/200)</td><td rowspan=1 colspan=1>97.25% - 99.99%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>96.47%(82/85)</td><td rowspan=1 colspan=1>90.03% - 99.27%</td><td rowspan=1 colspan=1>98.38% (973/989)</td><td rowspan=1 colspan=1>97.39% - 99.07%</td></tr></table>

# ORTHO T. cruzi ELISA Results and Most Probable T. cruzi Antibody Status among High Risk and Low Risk Subjects

Because the T. cruzi IFA is a non-reference standard for detection of antibodies to $T .$ . cruzi, the most probable T. cruzi antibody status of the high and low risk study subjects was determined by ORTHO T. cruzi ELISA Test System, comparator T. cruzi IFA and supplemental $T .$ cruzi RIPA testing according to a pre-specified testing algorithm. Specimens not tested with RIPA that were negative with both the ORTHO T. cruzi ELISA and the T. cruzi IFA were assigned a most probable T. cruzi antibody status of negative. Specimens tested with the RIPA were assigned a most probable T. cruzi antibody status of positive, negative or indeterminate based on the RIPA results.

A comparison of the ORTHO T. cruzi ELISA results to most probable T. cruzi antibody status is presented in the following table.

<table><tr><td rowspan=1 colspan=5>ORTHO T. cruzi ELISA Results and Most Probable T. cruzi Antibody Status in the High Risk and LowRisk Populations (N=1074)</td></tr><tr><td rowspan=2 colspan=1>ORTHO T. cruzi ELISAResults</td><td rowspan=1 colspan=3>Most Probable T. cruzi Antibody Status</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Indeterminate1</td><td rowspan=1 colspan=1>TOTAL</td></tr><tr><td rowspan=1 colspan=1>Repeatedly Reactive</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>975</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>976</td></tr><tr><td rowspan=1 colspan=1>TOTAL</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>981</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1074</td></tr><tr><td rowspan=1 colspan=5>1There were o . cruzi RIPA indeterminate results and therefore o specimens with a most probable . ziantibody status of indeterminate among the high and low risk specimens.</td></tr></table>

# Percent Agreement

The table below summarizes the percent agreement between the ORTHO T. cruzi ELISA and most probable T. cruzi antibody status. Data are listed by population and overall, with positive and negative percent agreement and $9 5 \%$ exact confidence intervals.

<table><tr><td rowspan=1 colspan=5>Positive and Negative Percent Agreement of the ORTHO T. cruzi ELISA with Most Probable T. cruzi AntibodyStatus by High Risk and Low Risk Study Population (N=1074)</td></tr><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>Positive PercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidence Interval</td><td rowspan=1 colspan=1>Negative PercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidence Interval</td></tr><tr><td rowspan=1 colspan=1>High Risk</td><td rowspan=1 colspan=1>98.92%(92/93)</td><td rowspan=1 colspan=1>94.15% - 99.97%</td><td rowspan=1 colspan=1>98.96%(476/481)</td><td rowspan=1 colspan=1>97.59% - 99.66%</td></tr><tr><td rowspan=1 colspan=1>Low Risk</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100%(300/300)</td><td rowspan=1 colspan=1>98.78% - 100%</td></tr><tr><td rowspan=1 colspan=1>PregnancyLow Risk</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>99.50%(199/200)</td><td rowspan=1 colspan=1>97.25% - 99.99%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>98.92%(92/93)</td><td rowspan=1 colspan=1>94.15% - 99.97%</td><td rowspan=1 colspan=1>99.39% (975/981)</td><td rowspan=1 colspan=1>98.67% - 99.78%</td></tr></table>

# Performance with Presumed T. cruzi Antibody Positive Populations

# Specimens Positive for $T .$ cruzi by Parasite Detection Methods

The sensitivity of the ORTHO T. cruzi ELISA Test System was evaluated among subjects classified as parasite positive by historical identification of $T .$ . cruzi parasites $\scriptstyle ( \mathrm { N } = 1 0 6 )$ . The samples were obtained from the endemic countries of Bolivia $( 2 7 . 3 \% )$ , Chile $( 4 0 . 6 \% )$ , Colombia $( 2 8 . 3 \% )$ , and Nicaragua $( 3 . 8 \% )$ , and were tested with the ORTHO T. cruzi ELISA at one testing site in St. Paul, MN. Specimens in this group were considered to have a most probable T. cruzi antibody status of positive. Assay sensitivity and $9 5 \%$ exact confidence interval are shown in the following table.

<table><tr><td rowspan=1 colspan=3>Sensitivity and 95% Exact Confidence Interval for the ORTHO T. cruzi ELISA inParasite Detection Positive Specimens (N=106)</td></tr><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>Sensitivity(%)</td><td rowspan=1 colspan=1>95% Exact ConfidenceInterval</td></tr><tr><td rowspan=1 colspan=1>Parasite Detection Positive</td><td rowspan=1 colspan=1>100%(106 / 106)</td><td rowspan=1 colspan=1>96.58% - 100%</td></tr></table>

# Specimens Presumed Positive for Antibodies to $T .$ cruzi by Serological Methods

# ORTHO T. cruzi ELISA versus T. cruzi IFA

A total of 810 specimens were included in the T. cruzi serological presumed positive population based upon two positive serological tests for $T .$ cruzi antibodies in use in the countries of origin (i.e., ELISA, IFA, hemagglutination, or complement fixation). The comparator T. cruzi IFA was not used to admit specimens to the study. The specimens were obtained from the endemic countries of Bolivia $( 1 7 . 8 \% )$ , Brazil $( 2 4 . 7 \% )$ , Chile $( 1 0 . 6 \% )$ , Guatemala $( 2 . 2 \% )$ , Mexico $( 3 2 . 5 \% )$ and Nicaragua $( 1 2 . 2 \% )$ . ORTHO T. cruzi ELISA testing was performed at two testing sites in Camp Hill, PA and Newark, NJ. Direct comparison of the ORTHO T. cruzi ELISA with the $T .$ . cruzi IFA is presented in the following table.

<table><tr><td rowspan=1 colspan=4>ORTHO T. cruzi ELISA vs. T. cruzi IFA Results in Specimens Presumed Positive by Serologic Methods(N=810)</td></tr><tr><td rowspan=2 colspan=1>ORTHO T. cruzi ELISAResult</td><td rowspan=1 colspan=2>T. cruzi IFA Result</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Repeatedly Reactive</td><td rowspan=1 colspan=1>565</td><td rowspan=1 colspan=1>99 2</td><td rowspan=1 colspan=1>664</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>141 3</td><td rowspan=1 colspan=1>146</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>570</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>810</td></tr><tr><td rowspan=1 colspan=4>These five specimens were also negative with the T. cruzi RIPA.2 Ninety-seven of these 99 specimens were also positive with the T. cruzi RIPA.All 141 specimens were negative with the T. cruzi RIPA.</td></tr></table>

# Percent Agreement

Positive, negative and overall percent agreement of the ORTHO T. cruzi ELISA with the $T .$ cruzi IFA and $9 5 \%$ exact confidence intervals are shown in the following table.

<table><tr><td rowspan=1 colspan=7>Positive, Negative and Overall Percent Agreement of the ORTHO . cruzi ELISA with the T. cruzi IFA in theSerological Presumed Positive Population (N=810)</td></tr><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>PositivePercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidenceInterval</td><td rowspan=1 colspan=1>NegativePercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidenceInterval</td><td rowspan=1 colspan=1>OverallPercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidenceInterval</td></tr><tr><td rowspan=1 colspan=1>SerologicalPreesumedPositive</td><td rowspan=1 colspan=1>99.13%(565/570)</td><td rowspan=1 colspan=1>97.96% -99.71%</td><td rowspan=1 colspan=1>58.75%(141/240)</td><td rowspan=1 colspan=1>52.24% -65.04%</td><td rowspan=1 colspan=1>87.16%(706/810)</td><td rowspan=1 colspan=1>84.66% -89.39%</td></tr></table>

# ORTHO T. cruzi ELISA versus Most Probable T. cruzi Antibody Status

Because the T. cruzi IFA is a non-reference standard for detection of antibodies to $T .$ . cruzi, the most probable $T .$ cruzi antibody status of the study subjects presumed positive by serologic methods was determined by ORTHO T. cruzi ELISA Test System, comparator T. cruzi IFA and supplemental T. cruzi RIPA testing according to a pre-specified testing and interpretation algorithm. Specimens that were ORTHO T. cruzi ELISA repeatedly reactive and positive with the T. cruzi IFA were assigned a most probable T. cruzi antibody status of positive and were not tested with the T. cruzi RIPA. All specimens negative with both assays or with discordant results between the two assays were tested with the T. cruzi RIPA and assigned a most probable T. cruzi antibody status based upon the RIPA results. A comparison of ORTHO T. cruzi ELISA results and most probable T. cruzi antibody status is presented in the following table

<table><tr><td rowspan=1 colspan=5>ORTHO T. cruzi ELISA Results and Most Probable T. cruzi Antibody Status in the SerologicalPresumed Positive Population (N=810)</td></tr><tr><td rowspan=2 colspan=1>ORTHO T. cruzi ELISAResults</td><td rowspan=1 colspan=3>Most Probable T. cruzi Antibody Status</td><td rowspan=2 colspan=1>TOTAL</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Indeterminate</td></tr><tr><td rowspan=1 colspan=1>Repeatedly Reactive</td><td rowspan=1 colspan=1>662</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>664</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>146</td></tr><tr><td rowspan=1 colspan=1>TOTAL</td><td rowspan=1 colspan=1>662</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>810</td></tr><tr><td rowspan=1 colspan=5>The were o T. cruziRIPA indeterminate results and therefore o specimens with a most probable T. ziantibody status of indeterminate among the serological presumed positive specimens tested with RIPA.</td></tr></table>

# Percent Agreement

Positive, negative and overall percent agreement of the ORTHO T. cruzi ELISA with most probable T. cruzi antibody status and $9 5 \%$ exact confidence intervals are shown in the following table.

<table><tr><td rowspan=1 colspan=7>Positive, Negative and Overall Percent Agreement of the ORTHO T. cruzi ELISA with Most ProbableT. cruzi Antibody Status for the Serological Presumed Positive Population (N=810)</td></tr><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>PositivePercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidenceInterval</td><td rowspan=1 colspan=1>NegativePercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidenceInterval</td><td rowspan=1 colspan=1>OverallPercentAgreement</td><td rowspan=1 colspan=1>95% ExactConfidenceInterval</td></tr><tr><td rowspan=1 colspan=1>SerologicalPresumedPositive</td><td rowspan=1 colspan=1>100%(662/662)</td><td rowspan=1 colspan=1>99.44% -100%</td><td rowspan=1 colspan=1>98.65%(146/148)</td><td rowspan=1 colspan=1>95.20% -99.84%</td><td rowspan=1 colspan=1>99.75%(808/810)</td><td rowspan=1 colspan=1>99.11% -99.97%</td></tr></table>

4. Clinical cut-off: NA

5. Expected values/Reference range: NA

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalent decision.